The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The revival of fosfomycin
Open accessAbstract
Fosfomycin, originally named phosphonomycin, was discovered in Spain in 1969. There are three forms of fosfomycin: fosfomycin tromethamine (a soluble salt) and fosfomycin calcium for oral use, and fosfomycin disodium for intravenous use. Fosfomycin is a bactericidal antibiotic that interferes with cell wall synthesis in both Gram-positive and Gram-negative bacteria by inhibiting the initial step involving phosphoenolpyruvate synthetase. It has a broad spectrum of activity against a wide range of Gram-positive and Gram-negative bacteria. It is highly active against Gram-positive pathogens such as Staphylococcus aureus and Enterococcus, and against Gram-negative bacteria such as Pseudomonas aeruginosa and Klebsiella pneumoniae. Its unique mechanism of action may provide a synergistic effect to other classes of antibiotics including beta-lactams, aminoglycosides, and fluoroquinolones. Oral fosfomycin is mainly used in the treatment of urinary tract infections, particularly those caused by Escherichia coli and Enterococcus faecalis. Intravenous fosfomycin has been administered in combination with other antibiotics for the treatment of nosocomial infections due to multidrug-resistant (MDR) Gram-positive and Gram-negative bacteria. Fosfomycin has good distribution into tissues, achieving clinically relevant concentrations in serum, kidneys, bladder wall, prostate, lungs, inflamed tissues, bone, cerebrospinal fluid, abscess fluid, and heart valves. Fosfomycin is well tolerated, with a low incidence of adverse events. Further randomized controlled trials are needed in order to evaluate the efficacy of intravenous fosfomycin for the management of nosocomial infections due to MDR pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE MECHANISM OF ACTION OF FOSFOMYCIN (PHOSPHONOMYCIN)
Kahan, F. M., Kahan, J. S., Cassidy, P. J., & Kropp, H. (1974) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1974.tb43277.x · Cited by 777
Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces
Hendlin, D., Stapley, E. O., Jackson, M., Wallick, H., Miller, A. K., Wolf, F. J., Miller, T. W., Chaiet, L., Kahan, F. M., Foltz, E. L., et al. (1969) · Science · doi:10.1126/science.166.3901.122 · Cited by 593
Falagas, M. E., Kastoris, A. C., Kapaskelis, A. M., & Karageorgopoulos, D. E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70325-1 · Cited by 487
Community Infections Caused by Extended-Spectrum β-Lactamase–Producing Escherichia coli
Rodríguez-Baño, J., Alcalá, J. C., Cisneros, J. M., Grill, F., Oliver, A., Horcajada, J. P., Tórtola, T., Mirelis, B., Navarro, G., Cuenca, M., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.17.1897 · Cited by 379
Souli, M., Galani, I., Antoniadou, A., Papadomichelakis, E., Poulakou, G., Panagea, T., Vourli, S., Zerva, L., Armaganidis, A., Kanellakopoulou, K., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649865 · Cited by 271
Vancomycin‐Resistant Enterococci: Mechanisms and Clinical Observations
Gold, H. S. (2001) · Clinical Infectious Diseases · doi:10.1086/321815 · Cited by 258
Modulatory effect of antibiotics on cytokine production by human monocytes in vitro
Morikawa, K., Watabe, H., Araake, M., & Morikawa, S. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.6.1366 · Cited by 211
Fosfomycin: an old, new friend?
Popovic, M., Steinort, D., Pillai, S., & Joukhadar, C. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0833-2 · Cited by 197
Falagas, M. E., Vouloumanou, E. K., Togias, A. G., Karadima, M., Kapaskelis, A. M., Rafailidis, P. I., & Athanasiou, S. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq237 · Cited by 157
Cao, M., Bernat, B. A., Wang, Z., Armstrong, R. N., & Helmann, J. D. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.7.2380-2383.2001 · Cited by 151
Cited by
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
Falagas, M. E., Vouloumanou, E. K., Samonis, G., & Vardakas, K. Z. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00068-15 · Cited by 612
Horsman, G. P., & Zechel, D. L. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00536 · Cited by 596
Sartelli, M., Chichom-Mefire, A., Labricciosa, F. M., Hardcastle, T., Abu-Zidan, F. M., Adesunkanmi, A. K., Ansaloni, L., Bala, M., Balogh, Z. J., Beltrán, M. A., et al. (2017) · World Journal of Emergency Surgery · doi:10.1186/s13017-017-0141-6 · Cited by 494
Antibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Metadata
- Authors
- Michalopoulos, A. S., Livaditis, I. G., & Gougoutas, V.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 15
- Issue
- 11
- Pages
- e732-e739
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W2130765730
- Cited by
- 378
- References
- 30
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The revival of fosfomycin. https://app.cochat.ai/papers/10.1016/j.ijid.2011.07.007
- The paper
- Michalopoulos, A. S., Livaditis, I. G., & Gougoutas, V. (2011). The revival of fosfomycin. International Journal of Infectious Diseases. https://doi.org/10.1016/j.ijid.2011.07.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.